167 related articles for article (PubMed ID: 18483257)
41. The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability.
Vargiolu M; Fusco D; Kurelac I; Dirnberger D; Baumeister R; Morra I; Melcarne A; Rimondini R; Romeo G; Bonora E
J Clin Endocrinol Metab; 2009 Jul; 94(7):2571-8. PubMed ID: 19366855
[TBL] [Abstract][Full Text] [Related]
42. High expression of the RET receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer.
Kakati RT; Kim H; Whitman A; Spanheimer PM
Breast Cancer Res Treat; 2023 Jun; 199(3):589-601. PubMed ID: 37061618
[TBL] [Abstract][Full Text] [Related]
43. Evolving pathway-driven biomarkers in breast cancer.
Ohshiro K; Kumar R
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S51-6. PubMed ID: 20374031
[TBL] [Abstract][Full Text] [Related]
44. Cell migration by a FRS2-adaptor dependent membrane relocation of ret receptors.
Lundgren TK; Stenqvist A; Scott RP; Pawson T; Ernfors P
J Cell Biochem; 2008 Jun; 104(3):879-94. PubMed ID: 18189271
[TBL] [Abstract][Full Text] [Related]
45. Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.
Brandt W; Mologni L; Preu L; Lemcke T; Gambacorti-Passerini C; Kunick C
Eur J Med Chem; 2010 Jul; 45(7):2919-27. PubMed ID: 20409618
[TBL] [Abstract][Full Text] [Related]
46. RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond.
Wu J; Subbiah V
Cancer Res; 2023 Oct; 83(19):3159-3161. PubMed ID: 37779428
[TBL] [Abstract][Full Text] [Related]
47. High glucose promotes cell proliferation and enhances GDNF and RET expression in pancreatic cancer cells.
Liu H; Ma Q; Li J
Mol Cell Biochem; 2011 Jan; 347(1-2):95-101. PubMed ID: 20960036
[TBL] [Abstract][Full Text] [Related]
48. ER-positive breast cancer cells are poised for RET-mediated endocrine resistance.
Horibata S; Rice EJ; Mukai C; Marks BA; Sams K; Zheng H; Anguish LJ; Coonrod SA; Danko CG
PLoS One; 2018; 13(4):e0194023. PubMed ID: 29608602
[TBL] [Abstract][Full Text] [Related]
49. Right on cue.
Lauffenburger DA
Nat Chem Biol; 2006 Nov; 2(11):569-70. PubMed ID: 17051228
[No Abstract] [Full Text] [Related]
50. Ret Receptor Has Distinct Alterations and Functions in Breast Cancer.
Gattelli A; Hynes NE; Schor IE; Vallone SA
J Mammary Gland Biol Neoplasia; 2020 Mar; 25(1):13-26. PubMed ID: 32080788
[TBL] [Abstract][Full Text] [Related]
51. Perturbation of hoxb5 signaling in vagal neural crests down-regulates ret leading to intestinal hypoganglionosis in mice.
Lui VC; Cheng WW; Leon TY; Lau DK; Garcia-Barcelo MM; Miao XP; Kam MK; So MT; Chen Y; Wall NA; Sham MH; Tam PK
Gastroenterology; 2008 Apr; 134(4):1104-15. PubMed ID: 18395091
[TBL] [Abstract][Full Text] [Related]
52. Steroid hormone modulation of RET through two estrogen responsive enhancers in breast cancer.
Stine ZE; McGaughey DM; Bessling SL; Li S; McCallion AS
Hum Mol Genet; 2011 Oct; 20(19):3746-56. PubMed ID: 21737465
[TBL] [Abstract][Full Text] [Related]
53. Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer.
Mechera R; Soysal SD; Piscuoglio S; Ng CKY; Zeindler J; Mujagic E; Däster S; Glauser P; Hoffmann H; Kilic E; Droeser RA; Weber WP; Muenst S
BMC Cancer; 2019 Jan; 19(1):41. PubMed ID: 30621641
[TBL] [Abstract][Full Text] [Related]
54. [Study on perineural infiltration in bile duct neoplasm--with special reference to the relationship with RET].
Fukuyoshi I
Hokkaido Igaku Zasshi; 2005 Jan; 80(1):21-30. PubMed ID: 15796028
[No Abstract] [Full Text] [Related]
55. Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancer.
Morandi A; Isacke CM
Breast Cancer Res; 2014 Jan; 16(1):301. PubMed ID: 24467886
[TBL] [Abstract][Full Text] [Related]
56. Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibition.
Gattelli A; García Solá ME; Roloff TC; Cardiff RD; Kordon EC; Chodosh LA; Hynes NE
Oncogene; 2018 Jul; 37(29):4046-4054. PubMed ID: 29695833
[TBL] [Abstract][Full Text] [Related]
57. Expression of the RET proto-oncogene is regulated by TFAP2C in breast cancer independent of the estrogen receptor.
Spanheimer PM; Woodfield GW; Cyr AR; Kulak MV; White-Baer LS; Bair TB; Weigel RJ
Ann Surg Oncol; 2013 Jul; 20(7):2204-12. PubMed ID: 22878616
[TBL] [Abstract][Full Text] [Related]
58. Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.
Griseri P; Garrone O; Lo Sardo A; Monteverde M; Rusmini M; Tonissi F; Merlano M; Bruzzi P; Lo Nigro C; Ceccherini I
Oncotarget; 2016 May; 7(18):26465-79. PubMed ID: 27034161
[TBL] [Abstract][Full Text] [Related]
59. RET signaling in breast cancer therapeutic resistance and metastasis.
Pecar G; Liu S; Hooda J; Atkinson JM; Oesterreich S; Lee AV
Breast Cancer Res; 2023 Mar; 25(1):26. PubMed ID: 36918928
[TBL] [Abstract][Full Text] [Related]
60. RET in breast cancer: functional and therapeutic implications.
Morandi A; Plaza-Menacho I; Isacke CM
Trends Mol Med; 2011 Mar; 17(3):149-57. PubMed ID: 21251878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
